Antibacterial Drugs: Commercial Prospects 2011-2026
20 Sep 2011 • by Natalie Aster
Bacterial diseases are one of the largest therapeutic areas in the pharmaceutical sector. This is primarily due to the high prevalence of bacterial infections around the world. In recent years the number of candidate drugs entering Phase III trials has fallen while the spread of bacterial resistance has increased. Generic competition has always been strong in this therapeutic area and this is set to continue over the period 2011 to 2026. This will be driven by patent expiries for some of the major brand names in the above antibacterial drug classes.
The report “Antibacterial Drugs: Commercial Prospects 2011-2026” by Visiongain focuses on the five leading categories: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems. In each category, market forecasts (2011-2026) are reported for the highest revenue generating drugs. The results for the individual drugs in those classes are described in greater detail.
Report Details:
Antibacterial Drugs: Commercial Prospects 2011-2026
Published: January 2011
Pages: 121
Price: US$ 2,461.00
Report Sample Abstract
The Indian Antibacterials Market, 2011-2026
As an emerging economy with significant infrastructure developments pending, India has done well to stimulate growth in its pharmaceutical sector. Much of this growth has occurred over the past two decades and has been linked to the growth in the Indian economy.
India is often compared with China in terms of economic development and the two countries are regional competitors. The antibacterials market in India lacks the size of its Chinese counterpart. The challenge for India is to accelerate its infrastructure developments programme while, at the same time, ensuring that it continues to grow its economy. Visiongain notes that good infrastructure will attract more multinational pharmaceutical companies to invest in the Indian antibacterials market.
The European Antibacterials Market, 2011-2026
As of the year 2010, individual countries within the European market have much lower percentage shares of the global antibacterials market when compared to the leading national markets of the US, China and Japan. This reflects the smaller size of these European countries compared with these leading national markets. In 2010, France had the highest market share of any European country. The UK had one of the lowest market shares of all European countries. By 2026, Visiongain predicts that France and Italy will remain the two leading European markets for sales of antibacterial agents.
More information can be found in the report “Antibacterial Drugs: Commercial Prospects 2011-2026” by Visiongain.
To order the report or ask for sample pages contact [email protected]
Contacts
MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Analytics & News
